Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Pfizer in trio of deals

Pfizer (NYSE:PFE) announced three deals on Monday covering compounds for HCV and schizophrenia and a genomic test for renal cell carcinoma. Pfizer

Read the full 229 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE